Mainz Biomed BV (MYNZ)

[BlazingStocks]

$MYNZ - Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer.
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html

[BlazingStocks]

Nice rebound off the low of the day... $MYNZ

[Elgordo84]

Get out while you can
This about to drop 50% from here.

[budfoxfun]

$MYNZ a $3.7 Billion Market Opportunity https://www.l3opptrk.com/3J67C1/3T3PPKJ/

[BlazingStocks]

$MYNZ holding steady, trading over 40% of its 10-day average volume, down slightly...

ColoAlert, Mainz Biomed's flagship product, combines the advantages of a colonoscopy and an occult blood test.
https://www.l3opptrk.com/3J67C1/3T3PPKJ/

[BlazingStocks]

$MYNZ trading nearly 2x over its average volume as we approach the last 30 minutes of the day... UP almost 16%!

[budfoxfun]

$MYNZ another strong close coming!

[budfoxfun]

+16.31% green in power hour!

MYNZ

[BlazingStocks]

$MYNZ trading 75% over its 10-day average volume as Power Hour approaches...but UP almost 15%. Looking great!

[BlazingStocks]

Good morning $MYNZ. Nice start to the day, UP almost 4%!

[BlazingStocks]

$MYNZ trading just under 45% of its 10-day average volume with 2.5 hours left in the day... Holding steady.

[BlazingStocks]

Nice move by $MYNZ!

As an integral part of her role, Ms. Edwards will manage the design and logistical operations of the Company’s multifaceted clinical trials - to include subjects in the US and EU - which support key stages of the FDA submission process for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). She will also develop and liaise closely with Key Opinion Leaders responsible for carrying out, or contributing to, both the European and US clinical studies and supporting related publications.

[budfoxfun]

Mainz Biomed recently announced a partnership with Dante Labs for the commercialization of ColoAlert in Europe and the United Arab Emirates (UAE).

MYNZ

[budfoxfun]

$MYNZ News Out! Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission https://finance.yahoo.com/news/mainz-biomed-appoints-vice-president-070100301.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[BlazingStocks]

$MYNZ Article June 10, 2022

AND THIS MOLECULAR GENETICS DIAGNOSTIC COMPANY MAY JUST HAVE THE ANSWER TO SAVE COUNTLESS LIVES WORLDWIDE.
https://www.l3opptrk.com/3J67C1/3T3PPKJ/

[BlazingStocks]

Great opportunity to load at these prices.

[budfoxfun]

Nice accumulation at these levels, ready for the next leg up!

MYNZ

[BlazingStocks]

$MYNZ trading just over 80% of its 10-day average volume as Power Hour approaches... thin after $11.50.

[BlazingStocks]

$MYNZ trading low volume compared to its 10-day average volume within the first 45 minutes of the day...but green, UP almost 1%.

[budfoxfun]

$MYNZ 19 Million Colonoscopies each year in USA https://www.l3opptrk.com/3J67C1/3S3Z2TD/

[BlazingStocks]

$MYNZ trading just nearly 15% over its 10-day average volume as we head into the last 20 minutes of the day...nice bounce off the lows!

[budfoxfun]

The ColoAlert patient kit is now CE marked to the IVDR requirements, a significant milestone and achievement for the company. The new, harmonized IVDR regulatory framework has been established to ensure the safety and performance of in-vitro diagnostic medical devices in the European market. Meeting conformity assessment requirements to IVDR compliance for ColoAlert, Mainz Biomed’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC), involves meeting new standards for the CE mark of its stool collection tool.

MYNZ

[BlazingStocks]

$MYNZ trading just under 30% of its 10-day average volume within the first 90 minutes... UP almost 2% on today's News.

[BlazingStocks]

“As a fast-growing organization and one looking to steadily unlock new global markets, it’s essential that we have watertight compliance across EU and other key jurisdictions,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The new IVDR framework is a major revision, focusing on patient safety and increasing the emphasis on the life-cycle management and continuous evaluation of products in the European market. While it significantly increases the regulatory burden for IVD manufacturers like ourselves, with the deep expertise of our team and existing sophistication of our internal processes and ColoAlert product, we’ve been able to successfully meet all the required criteria for compliance effectively and efficiently and in good time to meet the May 26th, 2022 deadline.”

[budfoxfun]

$MYNZ News Out! Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance https://finance.yahoo.com/news/mainz-biomed-successfully-completes-conformity-070100516.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo

[BlazingStocks]

Good morning $MYNZ! Nice close yesterday... looking for a continuation today.

[BlazingStocks]

$MYNZ Power Hour, L2 on the ASK is thin.

[budfoxfun]

$MYNZ huge opportunity in a $3.7 BILLION market opportunity with its blockbuster early detection test for Colorectal Cancer https://www.l3opptrk.com/3J67C1/3S3Z2TD/

[BlazingStocks]

$MYNZ trading 30% of its 10-day average volume with about 3 hours left in the day... holding steady on low volume.

[BlazingStocks]

ColoAlert, Mainz Biomed's flagship product, combines the advantages of  a colonoscopy and an occult blood test. $MYNZ

[BlazingStocks]

$MYNZ News May 19, 2022

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
https://finance.yahoo.com/news/mainz-biomed-dante-labs-announce-070100972.html

[budfoxfun]

Great levels to add here!

MYNZ

[BlazingStocks]

$MYNZ Article May 27, 2022

Here’s how Mainz BioMed could take full advantage of a $3.7 BILLION market opportunity with its blockbuster early detection test for Colorectal Cancer.
https://www.l3opptrk.com/3J67C1/3S3Z2TD/

[Investopotia]

New $MYNZ CEO interview: Detect Cancer Early & Increase Survival Rate Significantly

[AAAtrades]

are we expecting a lot of share dilution this year ?

I guess the european revenues will offset that.... would be nice if the euro revenues could reduce of even eliminate any future dilution... that would be superb

[Man6677]

Yes , i am watching the stock also,looking
promising in my opinion !

GLTA !

[AAAtrades]

I like the story here and the potential. I also like how MYNZ is up big in January relative to pretty much every other stock that has cratered.

The one thing that bugs me is that they already paid for some promo youtube videos. It just pisses me off how many companies keep doing this at such an early stage in their development. If they have a successful product and or strategy then why not just keep executing on it and shut up and not do any promos or paid promotions. If the business model and the product is for real, then people will eventually find out about it especially when big revenue kicks in.

[ReviveThomas]

IS this company a hot potato or what. No revenues yet? What is happening with this company.

[elmasry]

Yes i did my mistake

[crudeoil24]

lol, quite what? > I think you mean quiet!

[elmasry]

I am surprised this board is so quite

[crudeoil24]

Nice upside ..... 24.85 >

MYNZ

[crudeoil24]

Mainz Biomed Acquired Exclusive Rights to Novel mRNA Biomarkers; Said Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer
5:43 am ET January 5, 2022 (Benzinga) Print
Mainz Biomed N.V. (NASDAQ: MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert, the Company's highly efficacious, and easy-to-use detection test for colorectal cancer ("CRC"). Mainz is currently marketing ColoAlert in Europe through its unique business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. The Company is also preparing to initiate ColoAlert's regulatory pathway for approval in the United States.

Under the terms of the Technology Rights Agreement, the Company has the unilateral option to license the exclusive global rights to five gene expression biomarkers which have demonstrated a high degree of effectiveness in detecting CRC lesions including advanced adenomas ("AA"), a type of pre-cancerous polyp often attributed to this deadly disease. In a study evaluating these biomarkers published in the online peer review journal platform MDPI (March 11, 2021), study results achieved overall sensitivities of 75% for AA and 95% for CRC, respectively, for a 96% specificity outcome. If these statistical results are duplicated when the biomarkers are integrated into ColoAlert, we believe that it will ultimately position the Company's CRC test to be the most robust and accurate at-home diagnostic screening test on the market. It will not only detect cancerous polyps with a high degree of accuracy but has the potential to prevent CRC through early detection of precancerous adenomas.

"Securing the exclusive rights to license this family of novel biomarkers is a fantastic milestone for the Company as it provides an extraordinary opportunity to potentially upgrade ColoAlert's technical profile, possibly making it the most effective at-home screening test for CRC that has ever been commercialized," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "The Mainz team is on a mission to develop gold standard molecular diagnostic screening solutions for cancer indications and obtaining the rights to these biomarkers is a testament to our on-going commitment to develop cutting-edge products as they have shown superior sensitivity to even liquid biopsy products in development in terms of identifying advanced adenomas."

The Company will now commence a clinical study in Europe to evaluate the effectiveness of these biomarkers to enhance ColoAlert's utility in terms of extending its capability to include the identification of advanced adenomas, while increasing rates of diagnostic sensitivity and specificity. Given ColoAlert in its present form has already been CE-IVD marked (complying with EU safety, health and environmental requirements), the timeline and process to initiate this "add-on" study is expedited, and the Company is targeting the first half of 2022 to launch the clinical study. Furthermore, data generated by the study may potentially be incorporated into the Company's design of ColoAlert's U.S. clinical trial for consideration by the FDA.

[crudeoil24]

21.00 up 101%

MYNZ

[crudeoil24]

MYNZ going gangbusters in premarket!

[crudeoil24]

MYNZ > GOING GANGBUSTERS!

[Awl416]

Wild

[crudeoil24]

IPO today > Mainz Biomed (ticker: MYNZ) was the first of the group to begin trading, also on the Nasdaq. Shares kicked off at $14.35, hit a high of $17.48 and recently changed hands at $12.64, up 153% from its offer price.

Mainz Biomed was formed earlier this year to acquire PharmGenomics, a German biotech that makes in vitro diagnostic tests for the early detection of cancer, a prospectus said. Its flagship product, ColoAlert, is used to catch colorectal cancer. Another product in the early stages of research is PancAlert, which tests for pancreatic cancer. Mainz raised $10 million after selling 2 million shares at $5 each, the middle of its $4 to $6 price range.

[crudeoil24]

Mainz Biomed B.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.